The U.S. generics business continues to face severe price erosion and volume loss, with no near-term catalyst evident. Watch for further U.S. FDA inspection outcomes (six facilities inspected in H1 FY2027) and any resolution of the Revlimid antitrust litigation, which could create material liability. The Semaglutide quality issues add operational risk.
Price Chart
Executive Summary
Dr. Reddy's reported Q2 FY2027 (three months ended September 30, 2026) results showing a 2% YoY revenue decline to Rs.86,708 million and a 36% drop in net profit to Rs.9,134 million. The miss was driven by a 23% revenue decline in North America (U.S. generics price erosion and volume loss) and gross margin compression from 54.7% to 52.1%. The filing is bearish due to deteriorating core U.S. generics performance and falling profitability.
Key Facts
- Q2 FY2027 revenue Rs.86,708 million, down 2% YoY from Rs.88,051 million
- Net profit Rs.9,134 million, down 36% YoY from Rs.14,268 million
- North America (U.S./Canada) revenue fell 23% YoY to Rs.24,890 million; in USD terms, down 29%
- Gross margin contracted to 52.1% from 54.7% YoY
- Global Generics segment gross margin fell to 56.2% from 59.1% YoY
- PSAI segment gross margin collapsed to 11.8% from 18.0% YoY
- Basic EPS Rs.11.11 vs Rs.17.26 in prior year quarter
- Semaglutide recall in Canada recorded Rs.710 in expected product returns
- Semaglutide API issue led to Rs.2,230 inventory provision in Q1 FY2027
- India business grew 17% YoY; Russia grew 15% YoY (3% in RUB terms)
- Six new products launched in North America during the quarter
Financial Impact
Revenue decline of Rs.1,343 million YoY; net profit decline of Rs.5,134 million YoY; gross profit decline of Rs.2,936 million YoY
Risk Factors
- Continued U.S. generics price erosion and market share loss
- Semaglutide quality issues may lead to further write-offs or regulatory action
- U.S. FDA inspection observations at multiple facilities could lead to enforcement actions
- Revlimid antitrust litigation exposure (unascertainable liability)
- Geopolitical risks from Russia/Ukraine and Middle East operations
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001575872-26-000719 |
| Document: 0001575872-26-000719-index.html | 0001575872-26-000719 |
| Document: 0001575872-26-000719.txt | 0001575872-26-000719 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $13.65 | awaiting T+5 | — | $13.84 (+1.36%) |
Oct 26, 2026 1d ago | 6-K | $13.65 | awaiting T+5 | — | $13.84 (+1.36%) |
Oct 23, 2026 3d ago | 6-K | $13.21 | awaiting T+5 | — | $13.84 (−4.73%) |
Oct 23, 2026 3d ago | 6-K | $13.21 | awaiting T+5 | — | $13.84 (+4.73%) |
Oct 23, 2026 3d ago | 6-K | $13.21 | awaiting T+5 | — | $13.84 (+4.73%) |
Oct 23, 2026 3d ago | 6-K | $13.21 | awaiting T+5 | — | $13.84 (−4.73%) |
Oct 21, 2026 6d ago | 6-K | $13.19 | awaiting T+5 | — | $13.84 (+4.89%) |
Oct 14, 2026 12d ago | 6-K | $12.75 $13.19 | ▲ +3.45% | ▲ +3.00% | $13.84 (+8.51%) |
Oct 8, 2026 19d ago | 6-K | $12.20 $12.90 | ▲ +5.74% | ▲ +6.01% | $13.84 (+13.40%) |
Oct 7, 2026 20d ago | 6-K | $12.27 $12.75 | ▲ +3.91% | ▲ +4.89% | $13.84 (+12.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers